(Q39772563)

14 September 2017

1 reference

title

Antimalarials in the management of discoid and systemic lupus erythematosus (English)

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

systemic lupus erythematosus

26 June 2022

main subject

antimalarial

0 references

1 reference

based on heuristic

inferred from title

Anesthesiology and pain medicine

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

26 June 2022

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

26 June 2022

author name string

E. L. Dubois

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A358397

26 June 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=358397

26 June 2022

publication date

1 August 1978

1 reference

full work available at URL

14 September 2017

https://api.elsevier.com/content/article/PII:0049017278900331?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

https://api.elsevier.com/content/article/PII:0049017278900331?httpAccept=text/plain

26 June 2022

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Seminars in Arthritis and Rheumatism

26 June 2022

published in

1 reference

14 September 2017

8

1 reference

14 September 2017

33-51

1 reference

14 September 2017

1

1 reference

Treatment of lupus erythematosus with mepacrine

14 September 2017

2

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Quinacrine hydrochloride (atabrine) in the treatment of lupus erythematosus

6 April 2023

5

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Quinacrine hydrochloride (atabrine) in the treatment of lupus erythematosus

6 April 2023

8

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Quinacrine (atabrine) hydrochloride in treatment of discoid lupus erythematosus

6 April 2023

9

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

The treatment of lupus erythematosus with mepacrine and para-aminobenzoic acid

6 April 2023

10

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

The treatment of lupus erythematosus with mepacrine (Atabrine)

6 April 2023

11

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Therapeutic assays of the Skin and Cancer Unit of the New York University Hospital. Assay VII-Quinacrine hydrochloride (atabrine hydrochloride) for chronic discoid lupus erythematosus

6 April 2023

12

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Chloroquine diphosphate in treatment of discoid lupus erythematosus

6 April 2023

13

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Treatment of chronic discoid lupus erythematosus with chloroquine (araten).

6 April 2023

14

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Plaquenil sulfate in treatment of lupus erythematosus and light-sensitivity eruptions

6 April 2023

15

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Discoid lupus erythematosus treated with plaquenil

6 April 2023

16

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Plaquenil in the treatment of discoid lupus erythematosus; a preliminary report

6 April 2023

17

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Plaquenil in the treatment of lupus erythematosus

6 April 2023

18

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Amodiaquin (camoquin) in the treatment of chronic discoid lupus erythematosus; preliminary report, with special reference to the successful response of patients resistant to other antimalarial drugs

6 April 2023

19

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Antimalarials in the treatment of discoid lupus erythematosus; special reference to amodiaquin (camoquin)

6 April 2023

20

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Amodiaquine hydrochloride in the treatment of chronic discoid lupus erythematosus

6 April 2023

21

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Discoid lupus erythematosus; an analysis of its systemic manifestations

6 April 2023

22

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Treatment of lupus erythematosus with chloroquine; therapeutic results and a comparison of the value of chloroquine and mepacrine

6 April 2023

24

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Dermatologic clinics. 2. Antimalarial drugs in the therapy of lupus erythematosus

6 April 2023

25

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Synthetic antimalarial drugs in chronic discoid lupus erythematosus and light eruptions

6 April 2023

26

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Antimalarial therapy of lupus erythematosus

6 April 2023

27

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Quinacrine (atabrine) in treatment of systemic and discoid lupus erythematosus

6 April 2023

28

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Antimalarials in the treatment of rheumatoid arthritis

6 April 2023

30

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

General considerations in the treatment of systemic lupus erythematosus

6 April 2023

31

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

PLASMA quinacrine concentration as a function of dosage and environment

6 April 2023

32

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

STUDIES ON THE CHRONIC TOXICITY OF CHLOROQUINE (SN-7618)

6 April 2023

34

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Absorption of antimalarial drugs in human skin; spectroscopic and chemical analysis in epidermis and corium

6 April 2023

36

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Responses of the secretory coil of the human eccrine sweat gland to controlled injury

6 April 2023

37

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

PIGMENTATION FROM ANTIMALARIAL THERAPY. ITS POSSIBLE RELATIONSHIP TO THE OCULAR LESIONS.

6 April 2023

39

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

STUDIES ON THE PHARMACOLOGY OF CHLOROQUINE. RECOMMENDATIONS FOR THE TREATMENT OF CHLOROQUINE RETINOPATHY.

6 April 2023

40

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats

6 April 2023

41

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

The affinity of melanin for chloroquine.

6 April 2023

42

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

The Melanin Affinity of Chloroquine and Chlorpromazine Studied by Whole Body Autoradiography

6 April 2023

43

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

The action of ionizing radiation on DNA in the presence of quinacrine. I. UV absorption and fluorescence measurements

6 April 2023

47

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

The primary histologic lesion of seborrheic dermatitis and psoriasis

6 April 2023

48

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. I. The mechanism of action of hydroxychloroquine

6 April 2023

49

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

The failure of chloroquine to stimulate the human adrenal cortex.

6 April 2023

63

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Light eruptions and the ATP mechanism

6 April 2023

66

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Chloroquine (Aralen)-induced retinal damage

6 April 2023

67

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Effect of quinacrine (atabrine) upon lupus erythematosus phenomenon

6 April 2023

68

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

The reaction of the lupus erythematosus (L.E.) cell factor with deoxyribonucleoprotein of the cell nucleus

6 April 2023

70

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Affinity between the lupus erythematosus serum factor and cell nuclei and nucleoprotein

6 April 2023

72

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Antibodies to denatured deoxyribonucleic acid in lupus erythematosus serum. V. Mechanism of DNA-anti-DNA inhibition by chloroquine

6 April 2023

73

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

EFFECT OF CHLOROQUINE ON THE SULFHYDRYL GROUP AND THE DENATURATION OF BOVINE SERUM ALBUMIN.

6 April 2023

76

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Synthetic models of deoxyribonucleic acid complexes with antimalarial compounds. I. Interaction of aminoquinoline with adenine and thymine

6 April 2023

77

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Prevention of Postoperative Deep Venous Thrombosis and Pulmonary Embolism

6 April 2023

83

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Antimalarials: Effects on in vivo and in vitro Protein Synthesis

6 April 2023

85

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Chloroquine: mode of action

6 April 2023

86

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

In vitro inhibition of protein synthesis in the retinal pigment epithelium by chloroquine

6 April 2023

87

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Inhibition of murine RNA tumor virus replication and oncogenesis by chloroquine

6 April 2023

89

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Action of chloroquine phosphate in rheumatoid arthritis. II. Chromosome damaging effect

6 April 2023

90

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

SUPPRESSION OF IN VITRO LYMPHOCYTE RESPONSES BY CHLOROQUINE.

6 April 2023

91

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Action of chloroquine phosphate in rheumatoid arthritis. 1. Immunosuppressive effect

6 April 2023

92

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Evidence for a relationship between chloroquine and complement from studies with lymphocyte mitogens: possible implications for the mechanism of action of chloroquine in disease

6 April 2023

93

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Chloroquine, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists

6 April 2023

94

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Quinacrine is a prostaglandin antagonist

6 April 2023

95

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Dosage of Antimalarial Drugs for Children with Juvenile Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Clinical Study with Determination of Serum Concentrations of Chloroquine and Hydroxychloroquine

6 April 2023

97

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

An appraisal of chloroquine

6 April 2023

98

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Chloroquine retinopathy in patients with rheumatoid arthritis

6 April 2023

101

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Ocular toxicity of antimalarial drugs. Long-term follow-up

6 April 2023

102

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Quinacrine in the treatment of discoid lupus erythematosus: a five year follow-up survey; results and evaluation

6 April 2023

103

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Treatment of lupus erythematosus with mepacrine; results and relapses during a long observation

6 April 2023

104

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Melanosis caused by camoquin

6 April 2023

106

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Aplastic anaemia following mepacrine treatment of lupus erythematosus

6 April 2023

107

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Effect of Chloroquine on Morphology of Cytoplasmic Granules in Maturing Human Leukocytes—an Ultrastructural Study*

6 April 2023

109

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Experimental chloroquine myopathy

6 April 2023

113

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Vacuolar myopathy in systemic lupus erythematosus.

6 April 2023

114

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Vacuolar myopathy in a patient with positive LE cell preparations

6 April 2023

116

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Morphologic Study of a Neuromyopathy Caused by Prolonged Chloroquine Treatment

6 April 2023

117

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

6 April 2023

Chloroquine myopathy.

119

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Ototoxicity of Chloroquine

6 April 2023

123

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

STUDIES ON THE CHRONIC TOXICITY OF CHLOROQUINE (SN-7618)

6 April 2023

124

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Systemic lupus erythematosus: recent advances in its diagnosis and treatment

6 April 2023

125

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Pigmentation of the palate and subungual tissues associated with suppressive quinacrine hydrochloride therapy.

6 April 2023

126

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Unusual pigmentation developing after prolonged suppressive therapy with quinacrine hydrochloride

6 April 2023

127

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Variations in pigmentation from quinacrine. Report of case mimicking chronic hepatic disease

6 April 2023

130

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Amodiaquine hydrochloride. Corneal deposits and pigmented palate and nails after treatment of chronic discoid lupus erythematosus

6 April 2023

131

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

OCULAR LESIONS AFTER TREATMENT WITH CHLOROQUINE.

6 April 2023

133

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Corneal epithelial changes occurring during chloroquine (aralen) therapy.

6 April 2023

134

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Edema of cornea precipitated by quinacrine (atabrine)

6 April 2023

135

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Ocular abnormalities in patients treated with synthetic antimalarial drugs

6 April 2023

137

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Sjögren's syndrome in systemic lupus erythematosus. Clinical and subclinical manifestations

6 April 2023

139

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Unusual ocular lesions in a case of systemic lupus erythematosus

6 April 2023

141

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

HISTOPATHOLOGY OF CHLOROQUINE RETINAL TOXICITY.

6 April 2023

142

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

EXPERIMENTAL CHLOROAQUINE RETINOPATHY.

6 April 2023

144

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Incidence of chloroquine retinopathy

6 April 2023

145

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Chloroquine: ophthalmological safety, and clinical assessment in rheumatoid arthritis

6 April 2023

147

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Electroretinography in Patients with Connective Tissue Diseases Treated with Hydroxychloroquine

6 April 2023

149

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Delayed Onset of Chloroquine Retinopathy

6 April 2023

150

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Ophthalmological safety of chloroquine

6 April 2023

151

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Chloroquine retinopathy. Evaluation by fluorescein fundus angiography

6 April 2023

152

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Ocular Changes Induced by Long-Term Hydroxychloroquine (Plaquenil) Therapy

6 April 2023

153

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

Amodiaquine and hydroxychloroquine in rheumatoid arthritis

6 April 2023

157

1 reference

https://api.crossref.org/works/10.1016/0049-0172(78)90033-1

6 April 2023

Identifiers

1 reference

14 September 2017

1 reference